Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errorsiTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
“Encoding creativity” in drug discovery is a metaphor for how generative models learn patterns from molecular data and use them to propose new structures or optimize candidates against chosen objectives. It does not mean that a model understands biology, independently discovers a medicine, or proves that a proposed molecule works. A generated structure is an idea to evaluate—not a validated drug.
What does “encoding creativity” mean in drug discovery?
A molecule has to be represented in a form a computer can process before a model can learn from it or generate alternatives. The model learns statistical patterns in encoded examples, then can produce or rank candidate structures according to a task. In that limited sense, the system can appear creative: it recombines learned patterns into proposals that may not have appeared in its training examples.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Drugs: From Discovery to Approval | $59.12 | Buy on Amazon |
| 2 |
|
Basic Principles of Drug Discovery and Development | $268.00 | Buy on Amazon |
| 3 |
|
Textbook of Drug Design and Discovery | $55.19 | Buy on Amazon |
| 4 |
|
Computational Drug Discovery and Design (Methods in Molecular Biology, 2714) | $139.46 | Buy on Amazon |
| 5 |
|
Drugs: From Discovery to Approval | $135.33 | Buy on Amazon |
The metaphor has three practical parts:
- Learn: fit a model to encoded molecular examples so it captures patterns in that dataset.
- Generate: sample from the learned patterns or decode a representation into a candidate molecular structure.
- Steer: condition, rank, or optimize proposals toward selected molecular or biological properties.
Steering does not turn a score into evidence. A predicted property remains a model output until it is tested experimentally, and experimental results in turn are not the same as evidence from clinical studies.
How do generative AI models design new molecules?
They operate on representations, not on a chemist’s drawing as such. Reviews of generative chemistry describe string-based encodings, including randomized strings, and molecular graph representations in two or three dimensions. The chosen encoding determines how molecular structure is presented to the model and how generation or modification is carried out.
#1 Best Overall
| Representation | What it encodes | What to keep in mind |
|---|---|---|
| String | A molecular structure as a sequence of symbols. | Some approaches use randomized strings to represent molecules. A string is one way to encode structure, not a direct experimental test of the molecule. |
| 2D molecular graph | A molecule as a graph representation in two dimensions. | The model’s available structural information is shaped by this representation. |
| 3D graph or structure | A molecular representation that includes three-dimensional structure. | As with other encodings, the representation is part of the model design and does not itself establish biological activity. |
Generative approaches reviewed in the literature include recurrent neural networks, variational and adversarial autoencoders, generative adversarial networks, transformers, and reinforcement-learning hybrids. Newer work also addresses molecule and protein generation. These are families of techniques, not a universal ranking: a method’s suitability depends on the task, representation, data, and evaluation.
Can AI create a drug molecule from scratch?
It can generate a candidate structure, but saying it has created a drug overstates what generation establishes. A candidate still has to pass several distinct stages of scrutiny:
- Structure generation: the model outputs a molecular proposal.
- Computational assessment: software or models estimate properties or rank the proposal. These are predictions, not measurements.
- Synthesis and laboratory testing: researchers must establish whether the candidate can be made and test its behavior in relevant assays.
- Clinical and regulatory evidence: further evidence is needed to evaluate safety and effectiveness in people and support any regulatory decision.
A model’s ability to produce a novel-looking structure, or a favorable predicted score, does not establish success at the later stages.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →What does the evidence establish—and what does it not?
Martinelli and colleagues’ 2022 systematic review reported 87 studies found through database searching and 12 additional studies found through citation searching. That is the size of the review’s search, not a count of successful drugs or a current census of the field. The authors identified recurring challenges: generated-library homogeneity, deficient synthesizability, limited assay data, interpretability, multi-property optimization, incomparability, restricted molecule size, and uncertainty in model evaluation.
Rank #3
A 2024 survey organizes generative AI research around small-molecule generation and protein generation, and reviews subtasks, datasets, benchmarks, and architectures. Results on one benchmark do not, by themselves, show that a model performs well across drug discovery generally. The available reviews do not establish which architecture currently performs best, a clinical success rate attributable to generative AI, or the experimental validation status of a particular candidate.
How should you evaluate a molecule-generation result?
Novelty or a single predicted target property is not enough to judge whether a result is useful. When comparing systems, keep the following dimensions visible rather than collapsing them into one “best model” score:
| Evaluation dimension | Question to ask |
|---|---|
| Target task | Is the system generating small molecules, proteins, or another defined output? |
| Representation | Does it use strings, 2D graphs, 3D graphs, or another structure representation? |
| Generation and conditioning | How are candidates generated, and what objectives or conditions steer the output? |
| Data and assays | What data support the model, and how much relevant assay evidence is available? |
| Novelty and validity | How are novelty and structural validity measured? |
| Synthetic feasibility | Is there evidence that proposed molecules can be synthesized? |
| Optimization objectives | Which properties are optimized, and how are trade-offs among them handled? |
| Benchmark and validation design | What benchmark is used, and is there experimental validation beyond computational scoring? |
These questions matter because the reviews identify limited assay data, multi-property optimization, comparison across unlike tasks, and uncertainty in evaluation as persistent issues. A score is interpretable only in the context of the task, data, benchmark, and validation method that produced it.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Where do RDKit and regulatory guidance fit?
RDKit supports cheminformatics work
RDKit is an open-source cheminformatics toolkit. Its official documentation, version 2026.03.6, describes molecular operations in 2D and 3D and descriptor generation for machine learning, as well as installation guidance and a reference manual. It can support a computational workflow; it is not itself a generative drug-discovery system, and using it does not validate a candidate.
Best Value
FDA guidance distinguishes draft from final
As of October 9, 2026, FDA’s June 2026 M15 guidance, General Principles for Model-Informed Drug Development, is final and gives general recommendations for planning, evaluating, documenting, and reporting model-informed drug-development evidence.
FDA’s January 2025 guidance page on AI supporting regulatory decision-making identifies that guidance as a draft and “Not for implementation.” It proposes a risk-based framework for assessing credibility in a model’s particular context of use. The agency describes its scope this way: “This guidance provides recommendations to sponsors and other interested parties on the use of artificial intelligence (AI) to produce information or data intended to support regulatory decision-making regarding safety, effectiveness, or quality for drugs.” That wording is from the FDA’s January 2025 draft guidance page, not a final guidance document.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
